AmideBio
Business Services · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
331 S 104th St, Louisville, Colorado, 80...Phone Number
(303) 604-0296Website
www.amidebio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About AmideBio
AmideBio specializes in the development of novel peptide drug candidates aimed at addressing metabolic diseases through its in-silico design and peptide synthesis capabilities. The company also offers custom synthesis services and maintains a catalog of high-purity peptides for clients seeking cost-effective solutions. Their focus is on tackling significant therapeutic challenges in the metabolic disease sector. AmideBio serves a diverse range of clients in the pharmaceutical and biotechnology industries.Explore more
AmideBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AmideBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if AmideBio is spiking on competitors!
Check if AmideBio has recently received funding, and reach out quickly before it becomes old news!
Click to see if AmideBio had a recent Job posting/layoffs
Earning: See what the market has to say on AmideBio recently announced quarterly report
Product Launch: Get notified when AmideBio launches new products
Congratulate Masked Content for being promoted to Masked Content at AmideBio
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once AmideBio has new funding data
AmideBio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to AmideBio
Compare insights from companies similar to AmideBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
AmideBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
AmideBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about AmideBio.
AmideBio financials insights
Gather financial insights about AmideBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$763K
2022
Grant
$2.7M
AmideBio Tech Stack
A closer look at the technologies used by AmideBio
See more technologies
AmideBio News & Media
U.S. FDA grants rare pediatric disease designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism
BOULDER, Colo., Aug. 20, 2020 /PRNewswire/ -- AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease designation to...U.S. FDA grants orphan drug designation to AmideBio's glucagon analog for the treatment of congenital hyperinsulinism
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio's glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI). ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon – an effective treatment for CHI, but rendered impractical for long term administration given its instabiliDiabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio
BOULDER, Colo., May 16, 2018 /PRNewswire/ -- AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background developing drugs targeting diabetes at Eli Lilly &...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding AmideBio
Sign Up For FreeTo access detailed company insights
AmideBio specializes in the development of novel peptide drug candidates aimed at addressing metabolic diseases through its in-silico design and peptide synthesis capabilities. The company also offers custom synthesis services and maintains a catalog of high-purity peptides for clients seeking cost-effective solutions. Their focus is on tackling si... Read More
